United States & Pfizer
32 shared events · Importance 7 · Last updated Sep 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States: The US is drafting the investment rules through its Treasury Department, balancing national security concerns against pharmaceutical industry interests.
Pfizer: Pfizer has lobbied against broad restrictions and announced an up to $10.5 billion collaboration with Innovent Biologics covering 12 oncology programs.
Sep 18, 2026 · 6 articles
Tech
United States: The expanded approval of HYMPAVZI>>> by the United States — Food and Drug Administration>>> directly impacts the healthcare market and patients within the United States>>>.
Pfizer: The expanded approval of HYMPAVZI by the United States — Food and Drug Administration>>> is a significant positive development for Pfizer>>>, enhancing its product portfolio and market reach in the hemophilia treatment space. This approval is expected to boost Pfizer>>>'s revenue and solidify its position as a leader in rare disease therapies.
Jun 08, 2026 · 7 articles
Regulatory
United States: The U.S. is the primary market for the regulatory submission.
Pfizer: Pfizer is the applicant seeking FDA approval for its drug combination; positive regulatory news may support revenue growth.
Jul 22, 2026 · 6 articles
Tech
United States: The United States is the primary market for the Lyme disease vaccine, with a significant and expanding incidence of the disease. Regulatory approval within the United States, particularly from the United States — Food and Drug Administration, is crucial for the vaccine's availability.
Pfizer: Pfizer is a pharmaceutical company developing a new Lyme disease vaccine, which has shown 70-75% effectiveness in late-stage studies. The company plans to seek regulatory approval, which could significantly boost its market position in infectious disease prevention.
Apr 30, 2026 · 24 articles
Domestic
United States: The U.S. government, through the United States — White House, negotiated the drug pricing deals to lower costs for patients and reduce federal spending. The agreements are part of a broader push to make healthcare more affordable.
Pfizer: Pfizer was among the earlier 17 drugmakers that signed MFN deals, setting a precedent. The new agreements expand the framework to more companies.
Aug 18, 2026 · 37 articles
International
United States: The United States hosted the visit as part of UNGA 81 activities in New York, facilitating a US-Vietnam healthcare cooperation milestone. The event supports bilateral commercial and diplomatic ties.
Pfizer: Pfizer deepened its partnership with VNVC on vaccine immunisation and disease prevention capacity in Vietnam, reinforcing its emerging-market vaccine business. The cooperation document handover supports its long-term growth in Southeast Asia.
Sep 22, 2026 · 6 articles
Regulatory
United States: The U.S. is a key market for the vaccine, with high Lyme disease incidence and a large at-risk population.
Pfizer: Pfizer is the lead developer and would exclusively manufacture and commercialize the vaccine if approved. The EMA validation advances its pipeline and could provide a new revenue stream.
Aug 14, 2026 · 12 articles
Tech
United States: The United States Food and Drug Administration approved the RSVpreF vaccine in 2023, and the United States — Centers for Disease Control and Prevention provides statistics on RSV hospitalizations, highlighting the public health relevance of the vaccine within the nation.
Pfizer: Pfizer manufactures the RSVpreF vaccine, which has shown significant effectiveness in preventing RSV-associated hospitalizations in infants. This positive real-world data validates their product and could lead to increased sales and market share in the vaccine segment.
Jun 05, 2026 · 7 articles
Business
United States: The US stands to gain from increased investment and manufacturing, aligning with the Trump administration's priorities. The deal would likely require US regulatory approval.
Pfizer: Pfizer is referenced as a historical comparator, having attempted a hostile takeover of AstraZeneca in 2014. The current talks evoke memories of that failed bid.
Aug 02, 2026 · 60 articles
Regulatory
United States: The U.S. gains a new flu vaccine option, potentially improving public health outcomes for older adults.
Pfizer: Pfizer, a rival in mRNA vaccines, may face competitive pressure as Moderna expands its mRNA platform into flu.
Aug 05, 2026 · 105 articles
Business
United States: Home country of Pfizer entities involved in the transaction.
Pfizer: Seller of Minipress trademarks and discontinuing manufacture of Minipress XL; receives payment to Pfizer.
Sep 07, 2026 · 6 articles
Business
United States: Engaged in conflict with Iran, impacting oil prices and markets. Also intervened in yen markets.
Pfizer: Reported upbeat quarterly results, leading to a stock gain.
Jul 14, 2026 · 280 articles
Regulatory
United States: The U.S. is the primary location of the data center boom and the legal framework governing eminent domain.
Pfizer: Pfizer facility was the intended beneficiary of the Kelo seizure, but the company later left New London.
Jul 16, 2026 · 6 articles
Domestic
United States: The US has shifted toward a risk-based approach; Health Secretary Robert F. Kennedy Jr. has advocated stopping recommendations for children.
Pfizer: Pfizer's COVID-19 vaccine (with BioNTech) may see reduced demand in Germany; the company has faced scrutiny over adverse event data.
Jul 13, 2026 · 6 articles
Tech
United States: The U.S. is the primary market for the vaccine, with over 100,000 new melanoma cases expected annually. Regulatory approval and adoption in the U.S. will be crucial for the therapy's commercial success.
Pfizer: Pfizer, a partner of BioNTech, may benefit indirectly from the validation of mRNA technology in cancer treatment.
Aug 19, 2026 · 126 articles
International
United States: Accounts for 75% of computing power among top 500 AI supercomputers; home to many tech companies on the commission.
Pfizer: CEO Albert Bourla joined the AI for Good Global Commission.
Apr 20, 2026 · 123 articles
Accidents
United States: The United States>>> has repatriated its citizens from the MV Hondius and is monitoring them, with some placed under quarantine orders, demonstrating its efforts to manage potential imported cases.
Pfizer: Pfizer is mentioned in false conspiracy theories linking its vaccine to the Hantavirus outbreak, which health officials are working to counter.
May 07, 2026 · 368 articles
Domestic
United States: The United States is the setting for this event, with its federal health agencies and medical organizations involved in the vaccine recommendation dispute.
Pfizer: Pfizer's Abrysvo is mentioned as the only approved RSV vaccine for use in pregnancy, indicating its market position in this specific vaccine category.
Jun 10, 2026 · 6 articles
Tech
United States: The study population is U.S.-based, and findings may influence public health recommendations.
Pfizer: Andrew T. Chan served as a consultant; no direct impact.
Aug 17, 2026 · 20 articles
Business
United States: Its market accounts for the realized 9% U.S. price decline excluding rebates and is the base for the United States — Medicare GLP-1 Bridge Program expanding access.
Pfizer: Peer with only about 4.1% implied upside and Hold-skewed ratings, underscoring how Lilly stands out on analyst-implied returns within pharma.
Sep 14, 2026 · 6 articles
Tech
United States: The United States>>> is a key market for prostate cancer treatment, with a significant number of high-risk patients who could benefit from Apalutamide>>>.
Pfizer: Pfizer>>> is mentioned as a competitor with its ARPI drug Xtandi, indicating potential market competition with Johnson & Johnson>>>'s Apalutamide>>>.
May 31, 2026 · 6 articles
Business
United States: Clinical trial sites in the US are part of the study, but no direct impact on the country.
Pfizer: Pfizer has a non-exclusive license to Serina's POZ technology for LNP delivery, but this event does not directly affect Pfizer.
Jul 09, 2026 · 6 articles
Business
United States: Country where Palsonify is approved and where most patients reside.
Pfizer: Competitor in acromegaly market; PALSONIFY may compete with its treatments.
Jul 06, 2026 · 34 articles
Business
United States: Ascentage Pharma has a U.S. presence and FDA clearances, but this event does not directly impact the country.
Pfizer: Pfizer is a partner of Ascentage Pharma, but this event does not directly involve Pfizer.
Jul 26, 2026 · 6 articles
Regulatory
Pfizer: Pfizer had previously struck a deal with the administration to rein in prices and expects United States — Medicaid discounts to result in price and margin compression next year.
Dec 19, 2025 · 7 articles
+ 2 more events
View on Dashboard
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Pfizer interact across events, view sentiment trends, and discover connected entities.
Open Dashboard